Overview of Thoracic Oncology Trials in Cooperative Groups Around the Globe

详细信息    查看全文

• 作者：Ameen Abdulla Salahudeen¹ ; Manali I. Patel¹ ; Paul Baas² ; Walter J. Curran³ ; Jeffrey D. Bradley⁴ ; David R. Gandara⁵ ; Glenwood D. Goss⁶ ; Tony S. Mok⁷ ; Suresh S. Ramalingam¹ ; Everett E. Vokes⁸ ; Shakun M. Malik⁹ ; Heather A. Wakelee¹ ; ^{hwakelee@stanford.edu}
• 关键词：Cooperative group ; Mesothelioma ; NCTN ; NSCLC ; SCLC
• 刊名：Clinical Lung Cancer
• 出版年：2017
• 出版时间：January 2017
• 年：2017
• 卷：18
• 期：1
• 页码：5-12
• 全文大小：488 K
• 卷排序：18

文摘

Survival rates of patients with either early and advanced stage non–small-cell lung cancer (NSCLC) have improved with newer systemic therapy and radiation techniques, including combination regimens, targeted therapies, and immunotherapies. The cancer cooperative groups have historically played a critical role in the advancement of NSCLC therapy. Annually, representatives from cooperative groups worldwide convene at the International Lung Cancer Congress (ILCC). In summer 2015, the ILCC reached its 16th anniversary. This article highlights the NSCLC studies presented by participating groups in 2015.